evaluation of clinical benefit in sarcomas: modern imaging modalities
DESCRIPTION
Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities. Robert S. Benjamin, M.D. Department of Sarcoma Medical Oncology The SARCOMA Center. Thank you for your support!. Responders always live longer than “non-responders” unless they die of toxicity. FREIREICH’S LAW #9. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/1.jpg)
Evaluation ofClinical Benefit in Sarcomas:Modern Imaging Modalities
Robert S. Benjamin, M.D.Department of Sarcoma Medical Oncology
The SARCOMA CenterQuickTime™ and a
TIFF (Uncompressed) decompressorare needed to see this picture.
![Page 2: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/2.jpg)
Thank you for your support!
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 3: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/3.jpg)
FREIREICH’S LAW #9
•Responders always live longer than “non-responders” unless they die of toxicity.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 4: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/4.jpg)
80
0
20
100
50
10 12 14 16 18 2086420
Months
Hematological Improvement
No Hematological Improvement
Hematological Improvement minus duration of Improvement
% S
urv
ivin
g
Freireich, et al: J Chron Dis 14:593-608, 1961
Acute Lymphocytic Leukemia, ages 0-19
Survival vs. Time with Hematological Improvement
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 5: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/5.jpg)
0 5 10 15 20
0.0
0.2
0.4
0.6
0.8
1.0
Time to Treatment Failure in GISTby WHO Response at 4 weeks
Time (Months)
Pro
po
rtio
n F
ailu
re-F
ree >50% Response
<50% Response
Logrank p=0.96
Van den AbbeeleQuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 6: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/6.jpg)
+ + + +++ + ++++++ +++ +
++++++ +++
++++ +++++++++++ +++
++++++ +
++ + +++ + + + + + ++ +++ ++++++++++ ++++ +++++++ + +++++++ ++
Months
Time to Progression by RECIST
302724211815129630
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0 Nonresponders n=54 Responders n=44
p = 0.1
Response Rate 45%
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
Time to Treatment Failure in GISTby best Response by RECIST
![Page 7: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/7.jpg)
FREIREICH’S LAW #9
•Responders always live longer than “non-responders” unless they die of toxicity.
•Corollary: If not, you have not defined response correctly.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 8: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/8.jpg)
+ + ++++ +++++ ++ + ++++++++++++++ + +++++++++++++++++++++ ++
+++++++++++++++++++++++++ ++++
+
+
+++
+
+
++
+ +
+ + +++ +
Months
Time to Progression by Our Criteria
302724211815129630
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
Nonresponders n=17Responders n=81
p = 0.0002
Response Rate 83%
+ + + +++ + ++++++ +++ +
++++++ +++
++++ +++++++++++ +++
++++++ +
++ + +++ + + + + + ++ +++ ++++++++++ ++++ +++++++ + +++++++ ++
Months
Time to Progression by RECIST
302724211815129630
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0 Nonresponders n=54 Responders n=44
p = 0.1
Response Rate 45%
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 9: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/9.jpg)
We Should Desist Using RECIST
at Least in GIST
Robert S. Benjamin, M.D.Department of Sarcoma Medical Oncology
The SARCOMA Center
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 10: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/10.jpg)
Karnofsky Criteriafor Partial Response
• I-A distinct subjective benefit with favorable objective changes (% not specified) in all measurable criteria for 1 month or more.
• I-B objective regression of >50% for 1 month or more in a relatively asymptomatic patient.
Karnofsky DA: Meaningful clinical classification of therapeuticresponses to anticancer drugs. Clin Pharmacol Ther 2: 709, 1961.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 11: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/11.jpg)
Criteriafor Objective Response
• Surrogate marker for meaningful endpoint such as survival or time to progression.
• Objective, Quantifiable, Reproducible
Karnofsky DA: Meaningful clinical classification of therapeuticresponses to anticancer drugs. Clin Pharmacol Ther 2: 709, 1961.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 12: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/12.jpg)
Karnofsky Criteriafor Partial Response
• I-A distinct subjective benefit with favorable objective changes (% not specified) in all measurable criteria for 1 month or more.
• I-B objective regression of >50% for 1 month or more in a relatively asymptomatic patient.
Karnofsky DA: Meaningful clinical classification of therapeuticresponses to anticancer drugs. Clin Pharmacol Ther 2: 709, 1961.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 13: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/13.jpg)
WHO Criteriafor Partial Response
• >50% decrease in the sum of the products of perpendicular diameters of all measurable disease
• Absence of appearance of any new lesions
WHO handbook for reporting results of cancer treatment.Publication No. 48. Geneva. 1979.
Miller et al. Cancer 47: 207-214, 1981
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 14: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/14.jpg)
RECIST (Response Evaluation Criteria in Solid
Tumors)Partial Response
• >30% decrease in the sum of the single maximum diameters of all measurable disease
• Absence of appearance of any new lesions
Therase et al. JNCI 92: 205-216, 2000
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 15: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/15.jpg)
RECIST (Response Evaluation Criteria in Solid
Tumors)Partial Response
• Standardization and simplification• No major discrepancy in the
meaning and the concept of partial response to compare past and future results
• Not meant to discourage the development of new tools that may provide more reliable surrogate end pointsTherase et al. JNCI 92: 205-216, 2000
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 16: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/16.jpg)
Karnofsky Criteriafor Partial Response
• I-A distinct subjective benefit with favorable objective changes (% not specified) in all measurable criteria for 1 month or more.
• I-B objective regression of >50% for 1 month or more in a relatively asymptomatic patient.
Karnofsky DA: Meaningful clinical classification of therapeuticresponses to anticancer drugs. Clin Pharmacol Ther 2: 709, 1961.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 17: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/17.jpg)
25% Reduction as
Partial Response• Bonadonna: Adriamycin
– Karnofsky Criteria (Cancer Res. 30: 2572-2582, 1970)
– 25% Reduction (Tumori. 60: 373-391, 1974)
• Jaffe: High-Dose Methotrexate(Cancer. 30: 1627-1631, 1072)
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 18: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/18.jpg)
WHO Criteriafor Partial Response
“In the past, some groups and investigators have reported decreases of less than 50% in tumour size, but it is often not possible to determine this with precision.”
Ref. Moertel and Hanley
WHO handbook for reporting results of cancer treatment.Publication No. 48. Geneva. 1979.
Miller et al. Cancer 47: 207-214, 1981
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 19: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/19.jpg)
Moertel and Hanley
25% vs. 50%• 12 solid spheres covered by foam rubber up to 1.5 inches
thick
• 2 were identical and 2 others almost identical
• 16 experienced clinicians
• False positive responses:–25% reduction - 25%
–50% reduction - 6.8%
Cancer 38: 388-394, 1976
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 20: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/20.jpg)
BaselineBaseline 8 Weeks8 Weeks
Effects of Imatinib on GIST:CT findings
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 21: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/21.jpg)
What about Progression?
“We may differ about whether a patient qualifies for response, but we can all identify disease progression”
Verweij, Aarhus, April 2001 QuickTime™ and a
TIFF (Uncompressed) decompressorare needed to see this picture.
![Page 22: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/22.jpg)
WHO Criteriafor Progressive
Disease• >25% increase in the sum of the products of
perpendicular diameters of all measurable disease
• Appearance of any new lesions
• If progressive disease exists in any lesion or when a new lesion appears, then the overall result will be “progressive disease.”
WHO handbook for reporting results of cancer treatment.Publication No. 48. Geneva. 1979.
Miller et al. Cancer 47: 207-214, 1981
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 23: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/23.jpg)
WHO Criteria for Progressive Disease
“The use of a 25% increase in one or more measurable lesions or appearance of a new lesion is recommended for defining progression of disease. This percentage should not necessarily be regarded as influencing the management of the patient.”
WHO handbook for reporting results of cancer treatment.Publication No. 48. Geneva. 1979.
Miller et al. Cancer 47: 207-214, 1981
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 24: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/24.jpg)
RECIST (Response Evaluation Criteria in Solid
Tumors)
Progressive Disease• >20% increase in the sum of the single
maximum diameters of all measurable disease
• Appearance of any new lesions
• No comment about one or more areas of clear progression.
Therase et al. JNCI 92: 205-216, 2000
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 25: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/25.jpg)
RECIST (Response Evaluation Criteria in Solid
Tumors)
Progressive Disease• Standardization and simplification• No major discrepancy in the
meaning and the concept of partial response to compare past and future results
• Major discrepancy in the meaning and the concept of Progressive Disease prohibiting comparison past and future resultsTherase et al. JNCI 92: 205-216, 2000
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 26: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/26.jpg)
Size may not Matter
• Osteosarcomas may not shrink.
• Sarcomas can become fibrotic, cystic, or myxoid and not change in overall size substantially.
• Inaccurate response definitions may explain partially why prognostic factors for response and survival are different
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 27: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/27.jpg)
What about Functional Imaging?
• PET for metabolic activity.
• Dynamic Contrast-Enhanced MRI (or CT) for vascular changes.
• Better use of standard contrast-enhanced CT.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 28: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/28.jpg)
Challenge for this Symposium
• Explore the role of modern imaging in the evaluation of benefit or lack of benefit for sarcomas.
• Discuss the data over dinner after a break for the CTOS mixer.
• Reach a consensus on new, improved, criteria for response.
• Find a name.
• Publish our criteria.
QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
![Page 29: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/29.jpg)
What’s in a Name?• RECIST is a great name, but common
usage of RECIST (Response Evaluation Criteria in Solid Tumors) Criteria is redundant.
• New Names:– CTOS Criteria– SARC Criteria– Mixture: CTOS-SARC or SARC-CTOS– REIS (Response Evaluation in Sarcomas)
Criteria» Could be modified for other solid tumors
to REIST Criteria– ERIS (Evaluating Response in Sarcomas)
Criteria» Could be modified for other solid tumors
to ERIST CriteriaQuickTime™ and a
TIFF (Uncompressed) decompressorare needed to see this picture.
![Page 30: Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities](https://reader035.vdocuments.site/reader035/viewer/2022081603/568139be550346895da16338/html5/thumbnails/30.jpg)
Evaluation ofClinical Benefit in Sarcomas:Modern Imaging Modalities
Robert S. Benjamin, M.D.Department of Sarcoma Medical Oncology
The SARCOMA CenterQuickTime™ and a
TIFF (Uncompressed) decompressorare needed to see this picture.